

Lijun Rong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9066438/publications.pdf>

Version: 2024-02-01

68
papers

2,327
citations

270111

25
h-index

274796

44
g-index

72
all docs

72
docs citations

72
times ranked

2959
citing authors

#	ARTICLE	IF	CITATIONS
1	Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2940-2955.	2.9	102
2	ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2. <i>IScience</i> , 2022, 25, 103670.	1.9	29
3	Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants. <i>Nature Chemical Biology</i> , 2022, 18, 342-351.	3.9	63
4	Label-Free Digital Detection of Intact Virions by Enhanced Scattering Microscopy. <i>Journal of the American Chemical Society</i> , 2022, 144, 1498-1502.	6.6	26
5	Ebola Entry Inhibitors Discovered from <i>Maesa perularius</i> . <i>International Journal of Molecular Sciences</i> , 2022, 23, 2620.	1.8	2
6	Comparative analyses of small molecule and antibody inhibition on glycoprotein-mediated entry of Marburg virus with other filoviruses. <i>Journal of Medical Virology</i> , 2022, , .	2.5	2
7	Ebola Virus Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 155-170.	0.8	3
8	Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry. <i>Cell Reports</i> , 2022, 39, 110786.	2.9	37
9	3,4-Seco-Isopimarane Diterpenes from the Twigs and Leaves of <i>Isodon Flavidus</i> . <i>Molecules</i> , 2022, 27, 3098.	1.7	2
10	RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. <i>Journal of Medical Virology</i> , 2021, 93, 300-310.	2.5	82
11	Biological differentiation of traditional Chinese medicine from excessive to deficient syndromes in AIDS: Comparative microRNA microarray profiling and syndrome-specific biomarker identification. <i>Journal of Medical Virology</i> , 2021, 93, 3634-3646.	2.5	4
12	Punicalagin is a neuraminidase inhibitor of influenza viruses. <i>Journal of Medical Virology</i> , 2021, 93, 3465-3472.	2.5	23
13	Flu Universal Vaccines: New Tricks on an Old Virus. <i>Virologica Sinica</i> , 2021, 36, 13-24.	1.2	14
14	Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. <i>PLoS Pathogens</i> , 2021, 17, e1009312.	2.1	16
15	Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. <i>Cell and Bioscience</i> , 2021, 11, 45.	2.1	47
16	Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins. <i>Antiviral Research</i> , 2021, 186, 105013.	1.9	12
17	Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 2722-2734.	2.5	41
18	Stable Axially Chiral Isomers of Arylnaphthalene Lignan Glycosides with Antiviral Potential Discovered from <i>Justicia procumbens</i> . <i>Journal of Organic Chemistry</i> , 2021, 86, 5568-5583.	1.7	12

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 cell entry and targeted antiviral development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3879-3888.	5.7	21
20	Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. <i>Antiviral Research</i> , 2021, 190, 105075.	1.9	44
21	Signal-regulatory protein alpha is an anti-viral entry factor targeting viruses using endocytic pathways. <i>PLoS Pathogens</i> , 2021, 17, e1009662.	2.1	14
22	Current Development of Glioblastoma Therapeutic Agents. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1521-1532.	1.9	15
23	Small Molecule Inhibitors of Influenza Virus Entry. <i>Pharmaceuticals</i> , 2021, 14, 587.	1.7	23
24	Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1. <i>Frontiers in Immunology</i> , 2021, 12, 648815.	2.2	4
25	A recombinant Cedar virus based high-throughput screening assay for henipavirus antiviral discovery. <i>Antiviral Research</i> , 2021, 193, 105084.	1.9	5
26	Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors. <i>Science Advances</i> , 2021, 7, eabh2848.	4.7	87
27	Lignans and Their Derivatives from Plants as Antivirals. <i>Molecules</i> , 2020, 25, 183.	1.7	92
28	Screening for Anti-Influenza Actives of Prefractionated Traditional Chinese Medicines. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-7.	0.5	8
29	Development of coumarine derivatives as potent anti-filovirus entry inhibitors targeting viral glycoprotein. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112595.	2.6	10
30	Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11085-11099.	2.9	11
31	Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7211-7225.	2.9	16
32	A Mother-to-Child Transmission Study in Nigeria: The Impact of Maternal HIV Infection and HAART on Plasma Immunoglobulins, Cytokine Profiles and Infant Outcome. <i>Virologica Sinica</i> , 2020, 35, 468-477.	1.2	4
33	Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3120-3130.	2.9	21
34	Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus. <i>Antiviral Research</i> , 2020, 177, 104782.	1.9	13
35	Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors. <i>Frontiers in Microbiology</i> , 2020, 11, 182.	1.5	36
36	Structure of avian influenza hemagglutinin in complex with a small molecule entry inhibitor. <i>Life Science Alliance</i> , 2020, 3, e202000724.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Generation of a Reassortant Influenza A Subtype H3N2 Virus Expressing Gaussia Luciferase. <i>Viruses</i> , 2019, 11, 665.	1.5	8
38	A Parallel Phenotypic Versus Target-Based Screening Strategy for RNA-Dependent RNA Polymerase Inhibitors of the Influenza A Virus. <i>Viruses</i> , 2019, 11, 826.	1.5	15
39	Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus. <i>EBioMedicine</i> , 2019, 47, 269-283.	2.7	34
40	Competitive Cooperation of Hemagglutinin and Neuraminidase during Influenza A Virus Entry. <i>Viruses</i> , 2019, 11, 458.	1.5	52
41	LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. <i>Frontiers in Immunology</i> , 2019, 10, 6.	2.2	280
42	Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. <i>Current Medicinal Chemistry</i> , 2019, 25, 5115-5127.	1.2	60
43	Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease. <i>Current Medicinal Chemistry</i> , 2019, 25, 5177-5190.	1.2	9
44	A Mechanism Underlying Attenuation of Recombinant Influenza A Viruses Carrying Reporter Genes. <i>Viruses</i> , 2018, 10, 679.	1.5	14
45	Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. <i>Viruses</i> , 2018, 10, 678.	1.5	24
46	Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. <i>Antiviral Research</i> , 2018, 157, 47-56.	1.9	24
47	Identification of Ellagic Acid from Plant <i>Rhodiola rosea</i> L. as an Anti-Ebola Virus Entry Inhibitor. <i>Viruses</i> , 2018, 10, 152.	1.5	45
48	A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase. <i>Viruses</i> , 2018, 10, 325.	1.5	15
49	Anti-HIV diphyllin glycosides from <i>Justicia gendarussa</i> . <i>Phytochemistry</i> , 2017, 136, 94-100.	1.4	51
50	Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant <i>Justicia gendarussa</i> . <i>Journal of Natural Products</i> , 2017, 80, 1798-1807.	1.5	71
51	Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546. <i>ACS Infectious Diseases</i> , 2017, 3, 330-335.	1.8	15
52	Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor. <i>Antiviral Research</i> , 2017, 145, 24-32.	1.9	26
53	Cell-Based High-Throughput Screening Assay Identifies 2-Deoxy-2-Fluoro-2-Deoxycytidine Gemcitabine as a Potential Antipoliiovirus Agent. <i>ACS Infectious Diseases</i> , 2017, 3, 45-53.	1.8	17
54	Stabilization and Improvement of a Promising Influenza Antiviral: Making a PAIN PAINless. <i>ACS Infectious Diseases</i> , 2016, 2, 608-615.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Bis-biguanide dihydrochloride inhibits intracellular replication of <i>M. tuberculosis</i> and controls infection in mice. <i>Scientific Reports</i> , 2016, 6, 32725.	1.6	8
56	Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions. <i>Journal of Biomolecular NMR</i> , 2016, 64, 255-265.	1.6	18
57	Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry. <i>Journal of Virology</i> , 2015, 89, 5441-5449.	1.5	54
58	Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. <i>Journal of Virology</i> , 2015, 89, 9932-9938.	1.5	90
59	Novel Small Molecule Entry Inhibitors of Ebola Virus. <i>Journal of Infectious Diseases</i> , 2015, 212, S425-S434.	1.9	49
60	A parallel genome-wide RNAi screening strategy to identify host proteins important for entry of Marburg virus and H5N1 influenza virus. <i>Virology Journal</i> , 2015, 12, 194.	1.4	12
61	A Comparative High-Throughput Screening Protocol to Identify Entry Inhibitors of Enveloped Viruses. <i>Journal of Biomolecular Screening</i> , 2014, 19, 100-107.	2.6	37
62	Mutagenesis Studies of the H5 Influenza Hemagglutinin Stem Loop Region. <i>Journal of Biological Chemistry</i> , 2014, 289, 22237-22245.	1.6	10
63	New Small Molecule Entry Inhibitors Targeting Hemagglutinin-Mediated Influenza A Virus Fusion. <i>Journal of Virology</i> , 2014, 88, 1447-1460.	1.5	72
64	Inhibition of Influenza H7 Hemagglutinin-Mediated Entry. <i>PLoS ONE</i> , 2013, 8, e76363.	1.1	25
65	Identification of critical residues of influenza neuraminidase in viral particle release. <i>Virology Journal</i> , 2011, 8, 14.	1.4	17
66	Characterization of the receptor-binding domain of Ebola glycoprotein in viral entry. <i>Virologica Sinica</i> , 2011, 26, 156-70.	1.2	19
67	Identification of a New Region of SARS-CoV S Protein Critical for Viral Entry. <i>Journal of Molecular Biology</i> , 2009, 394, 600-605.	2.0	31
68	Comprehensive Analysis of Ebola Virus GP1 in Viral Entry. <i>Journal of Virology</i> , 2005, 79, 4793-4805.	1.5	144